During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
The Survey highlighted that Indian pharmaceutical exports achieved a healthy growth of 24 per cent in FY21 and expressed hope that India’s domestic pharmaceutical market is estimated to grow to US $65 billion by 2024 from estimated US $41 billion in 2021
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
Sanjeev is currently the Country President for AstraZeneca Malaysia
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
The 9th World Ayurveda Congress and Arogya Expo 2022 aims to showcase the efficacy and strength of the AYUSH systems of medicine at the global level
Subscribe To Our Newsletter & Stay Updated
